See2cure

See2cure detects the invisible to improve surgery and reduce recurrence of abdominal cancers using a targeted fluorescent guidance technology. This project addresses a major clinical challenge: the treatment of microscopic abdominal metastases, a frequent consequence of colorectal, gastric, ovarian and pancreatic cancers, which affect more than one million people worldwide every year. The innovative see2cure protein platform has been designed as a fluorescent targeting tracer. It specifically detects these metastases by recognising its molecular target during fluorescence-guided surgery, whether open (laparotomy) or minimally invasive (laparoscopy). The aim of this technology is to improve surgical results and reduce recurrence, which currently affects 75% of patients after first line treatment. It enables early and targeted detection of lesions that are invisible to the naked eye.